Sign up USA
Proactive Investors - Run By Investors For Investors

Affimed teams up with Merck for cancer drug trial

The Phase 1b trial is expected to will be funded and conducted by Affimed, and it is expected to get underway in the first half of 2016.
Affimed teams up with Merck for cancer drug trial
Patient derived models showed up to 90% of a tumour could be eradicated.

Cancer drug developer Affimed N.V. (NASDAQ:AFMD) has struck a collaboration agreement with Merck which will involve a new drugs trial for patients with Hodgkin lymphoma.

Nasdaq quoted Affimed, which is headquartered in Germany, will fund and conduct the Phase 1b trial in which it will combine Merck's KEYTRUDA (pembrolizumab) drug, with Affimed's proprietary  candidate AFM13.

The trial will involve patients with Hodgkin lymphoma whose disease has relapsed or is refractory to chemotherapy. Its purpose will be to establish a dosing regimen, as well as assessing safety and efficacy.

It is expected that the study will begin in the first half of this year.

"AFM13, a first-in-class NK-cell engager, has shown an acceptable safety profile and preliminary antitumor activity in the first-in-human Phase 1 study,” said Dr Adi Hoess, Affimed chief executive.

“Additionally, preclinical studies indicate that a combination with an anti PD-1 therapy could act synergistically and represent an additional future treatment option for patients."

NK (or Natural Killer) cells are important in the activation of the innate immune system and the subsequent killing of tumor cells, Affimed explained in a statement.

The company also highlighted that in patient derived models at Stanford University AFM13, in combination with an anti-PD-1 antibody (Merck’s KEYTRUDA is an example of this kind of drug) demonstrated “impressive synergy” with up to 90% of the tumor eradicated.

Dr Eric Rubin, a vice president and therapeutic area head at Merck Research Laboratories,  meanwhile, said: "Evaluating the potential for innovative combination therapies through strategic collaborations in difficult-to-treat tumor types continues to be an important part of our clinical development program for KEYTRUDA.”

"In partnering with companies such as Affimed, we continue our efforts to bring forward new scientific breakthroughs for patients with Hodgkin lymphoma and the field of immuno-oncology overall."


Register here to be notified of future INDU Company articles
View full INDU profile

US Market News Timeline

Related Articles

picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
November 22 2016
With the balance sheet now significantly strengthened, we anticipate the company is well-positioned to capture value in areas where its technology platforms offer material improvements for patient care - Panmure Gordon.
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use